Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06888921 · ClinicalTrials.gov registry record · Phase 1
A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer
A Phase 1 study of Ovarian Cancer and Ovarian Cancer Recurrent, sponsored by Compugen.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
- 20
- Study locations
NCT06888921 is a Phase 1 study of Ovarian Cancer and Ovarian Cancer Recurrent that is actively recruiting participants, run by Compugen. The registered enrollment target is 60 participants, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 14 states.
The verdict
NCT06888921, a Phase 1 study of Ovarian Cancer and Ovarian Cancer Recurrent, is actively recruiting participants, sponsored by Compugen.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, when used as a maintenance treatment, stop or slow the progression of ovarian cancer? * Does COM701 delay the time to needing a new anti-cancer treatment? * What side effects do participants have when taking COM701? Participants will: * Visit the clinic once every 3 weeks during which the study treatment will be administered intravenously * Undergo various tests and procedures to monitor general health throughout the trial including physical examinations, vital sign measurements (heart rate, blood pressure, breathing, and body temperature), weight measurements, electrocardiography (ECG), blood and urine tests and pregnancy tests if relevant. * Undergo various tests and procedures to assess disease response throughout the trial including tumor imaging by CT scans or MRI to assess the tumor, its location, and size, and the testing of a sample of tumor tissue (from a prior biopsy or a fresh biopsy if feasible, to evaluate tumor response to treatment and to measure levels of tumor markers,
Conditions Studied
Interventions
- DRUG Normal Saline
- DRUG COM701
Study Locations (20)
Other
- Centre Oscar Lambret - Lille
- Institut Paoli-Calmettes - Marseille
- Hospices Civils de Lyon- Centre Hospitalier Lyon Sud - Pierre-Bénite
- Centre Eugene Marquis - Rennes
Illinois
- The University of Chicago Medical Center - Chicago
- Northwestern Memorial Hospital - Warrenville
New York
- Memorial Sloan Kettering Cancer Center- Main Campus - New York
- University of Rochester Medical Center - Rochester
France
- Centre Hospitalier Regional et Universitaire de Besancon - Hopital Jean-Minjoz - Besançon
- Oncopole Claudius Regaud - Toulouse
Georgia
- Georgia Cancer Center at Augusta University - Augusta
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- Corewell Health - Grand Rapids
North Carolina
- Levine Cancer Institute - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2025-07-21 |
| Est. Completion | 2027-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06888921
The ClinicalTrials.gov registry entry for NCT06888921 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 729-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (92% lower). The listed sponsor is Compugen, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 2 interventions - of which Normal Saline is the first listed.
NCT06888921 reports 20 study locations spanning 14 distinct geographic areas - top geographies include Other, Illinois, New York.
Frequently Asked Questions
What is clinical trial NCT06888921 about?
NCT06888921 is a clinical study titled "A Clinical Trial to Evaluate the Safety and Efficacy of COM701 in Relapsed Platinum Sensitive Ovarian Cancer". The goal of this clinical trial is to learn if the experimental antibody COM701 delays the progression of ovarian cancer in participants with Relapsed Platinum Sensitive Ovarian Cancer. It will also learn about the safety of COM701. The main questions the trial aims to answer are: * Does COM701, w...
What is the current status of trial NCT06888921?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2025-07-21. Estimated completion is 2027-03.
What conditions does trial NCT06888921 study?
This clinical trial studies the following conditions: Ovarian Cancer, Ovarian Cancer Recurrent.
What interventions are being tested in trial NCT06888921?
The interventions under investigation include: Normal Saline (DRUG), COM701 (DRUG).
Who is sponsoring clinical trial NCT06888921?
This trial is sponsored by Compugen, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06888921 being conducted?
This trial has 20 study locations across Georgia, Illinois, Massachusetts, Michigan, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
RECRUITING · Phase 1
-
A Study to Assess Adverse Events, Change in Disease Activity and How Intravenous (IV) ABBV901 Moves Through the Body Alone or in Combination With Bevacizumab in Adult Participants With Ovarian Cancer
RECRUITING · Phase 1
-
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies
RECRUITING · Phase 1
-
Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RECRUITING · Phase 1
-
A Study of MT-4561 in Patients With Various Advanced Solid Tumors
RECRUITING · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.